PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of DirectorsGlobeNewsWire · 4 days ago
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal CancerMarketBeat · Oct 15, 2026
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer TranscriptSeeking Alpha · Oct 15, 2026
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research · Oct 14, 2026
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver MetastasesGlobeNewsWire · Oct 6, 2026
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest UpdateDefense World · Sep 27, 2026PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.13 | -$0.18 | Miss |
| May 13, 2026 | -$0.15 | -$0.13 | Beat |
| Mar 30, 2026 | -$0.20 | -$0.14 | Beat |
| Nov 13, 2025 | -$0.21 | -$0.19 | Beat |
| Aug 13, 2025 | -$0.24 | -$0.21 | Beat |
| May 14, 2025 | -$0.25 | -$0.21 | Beat |